<DOC>
	<DOCNO>NCT02192151</DOCNO>
	<brief_summary>To evaluate safety investigate pharmacokinetic property bioavailability PHN131 healthy volunteer</brief_summary>
	<brief_title>Study PHN131 Healthy Volunteers</brief_title>
	<detailed_description>1 . Efficacy endpoint ( ) : pharmacokinetic property bioavailability PHN131 The efficacy endpoint pharmacokinetic property administer PHN131 concentration nalbuphine plasma pharmacokinetic parameter PHN131 analyze concentration nalbuphine plasma . The bioavailability PHN131 calculate pharmacokinetic parameter PHN131 NubainÂ® injection . 2 . Safety evaluation : The safety evaluation include vital sign monitor blood pressure , pulse rate , body temperature respiratory rate treatment period .</detailed_description>
	<criteria>Each subject must meet follow criterion enrol study : 1 . Normal healthy adult subject 20 40 year age . 2 . Body weight within 80 120 % ideal body weight . The ideal body weight define : ( subject ' height 80 ) x 0.7 3 . Acceptable medical history physical examination include : Normal chest Xray ECG result within six month prior Treatment Period dose . No particular clinical significance general disease history within two month prior Treatment Period dose . 4 . Acceptable clinical laboratory determination without significant deviation normal value within two month prior Treatment Period dose , include AST , ALT , garmaGT , alkaline phosphatase , total bilirubin , albumin glucose , BUN , uric acid , creatinine , total cholesterol triglyceride ( TG ) . 5 . Acceptable hematology within two month prior study , include hemoglobin , hematocrit , red blood cell , MCV , MCH , MCHC , white blood cell platelet . 6 . Acepatable urinalysis within two month prior study , include pH , urine glucose protein . 7 . Signed write informed consent participate study . Subjects meet follow criterion exclude study : 1 . Recent history drug alcohol addiction abuse . 2 . A clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine neurologic system ( ) psychiatric disease ( determined clinical investigator ) . 3 . History allergic response ( ) nalbuphine relate drug . 4 . History clinically significant allergy include drug allergy allergic bronchial asthma . 5 . Evidence chronic acute infectious disease . 6 . Any clinically significant illness surgery 4 week prior Treatment Period dose ( determined clinical investigator ) . 7 . Taking drug know induce and/or inhibit hepatic drug metabolism within one month prior Treatment Period dose . 8 . Receiving investigational drug within one month prior Treatment Period dose . 9 . Taking prescription medication nonprescription medication within two week prior Treatment Period dose . 10 . Donating great 150 ml blood within two month prior Treatment Period dose donate plasma ( e.g . plasmapheresis ) within 14 day prior Treatment Period dose . All subject advise donate blood 4 week complete study . 11 . Consumption caffeine , xanthinecontaining product ( i.e . coffee , tea , caffeinecontaining soda , cola chocolate , etc . ) and/or alcohol least 48 hour prior day dose schedule period blood sample collect . 12 . Any medical reason ( ) determine clinical investigator . 13 . Patient pregnant breastfeeding . Women childbearing potential positive urine pregnancy test baseline .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Analgesic</keyword>
	<keyword>Narcotics</keyword>
	<keyword>Opioids</keyword>
	<keyword>Non-scheduled substanse</keyword>
</DOC>